• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Robyn Barberry
          • Hanael Bianchi
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Books/CDs/Prayer Cards
        • CR Media platforms
        • Electronic Edition
  • Advertising
  • Shop
        • Purchase Photos
        • Books/CDs/Prayer Cards
        • Magazine Subscriptions
        • Archdiocesan Directory
  • CR Radio
        • CR Radio
        • Protagonistas de Fe
  • News Tips
  • Subscribe
Boxes of mifepristone, the first pill given in a medical abortion, are pictured in a Jan. 13, 2023, photo. (OSV News photo/Evelyn Hockstein, Reuters)

Appeals court rules to keep abortion pill on the market but reinstates prior restrictions

April 13, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, World News

Share
Share on Facebook
Share
Share this
Pin
Pin this
Share
Share on LinkedIn

WASHINGTON (OSV News) — A federal appeals court April 12 froze portions of a federal judge’s ruling suspending the U.S. Food and Drug Administration’s approval of a medication abortion pill, ruling that the drug can remain on the market but under more strict regulations while a challenge to it plays out.

The Justice Department said it would seek emergency relief from the Supreme Court over the appeals court’s ruling.

A three-judge panel of the 5th U.S. Circuit Court of Appeals agreed to temporarily block U.S. District Judge Matthew Kacsmaryk’s ruling, issued on Good Friday, which suspended the FDA’s approval of the drug mifepristone, the first of two drugs used in a medication or chemical abortion.

But in a 2-1 vote, the panel permitted other portions of that ruling to take effect, prohibiting mifepristone’s use after seven weeks of pregnancy and its distribution by mail, regulations that were in place prior to 2016 on a drug originally approved by the agency in 2000.

A box of the RU-486 drug, known generically as mifepristone and by its brand name Mifeprex, is seen in an undated handout photo.(OSV News photo/courtesy Danco Laboratories)

In an April 13 statement, Attorney General Merrick Garland said the Justice Department “strongly disagrees with the Fifth Circuit’s decision in Alliance for Hippocratic Medicine v. FDA to deny in part our request for a stay pending appeal.”

“We will be seeking emergency relief from the Supreme Court to defend the FDA’s scientific judgment and protect Americans’ access to safe and effective reproductive care,” Garland said.

A coalition of pro-life opponents of the drug mifepristone sought for the FDA’s approval of the drug to be revoked, arguing the government violated its own safety standard in approving the drug more than two decades ago.

Pro-life and pro-abortion activists recognized the mixed results of the appeals court ruling, with pro-life activists applauding reinstated restrictions and pro-abortion activists applauding that the drug will remain on shelves for the time being.

Jeanne Mancini, president of the March for Life, said in a statement that “we are pleased that the 5th Circuit Court of Appeals has temporarily reinstated important and commonsense health and safety protections surrounding the use of chemical abortion drugs.”

“The FDA’s elimination of these safeguards shows a reckless disregard for women’s health when it comes to abortion,” Mancini said. “This dangerous drug regimen has been shown to harm women, sometimes fatally, in addition to ending the lives of unborn children.”

NARAL Pro-Choice America President Mini Timmaraju said in a statement that “once again, we see that our court system has been rigged by the far-right to deliver results that are undemocratic and dangerous.”

“We’re relieved that the FDA’s approval of mifepristone stands for now, but by reinstating outdated and unnecessary restrictions, these judges — many of whom were appointed by a twice-impeached now-indicted former president — put tens of millions of people’s health at risk,” Timmaraju argued. “Anti-choice extremists want to ban all abortion, everywhere. They can’t win elections, so they’ve turned to the courts to do their dirty work. As this legal fight goes on, our reproductive freedom champions across the country must work to protect access to medication abortion no matter what happens next in the courts.”

But Katie Daniel, Susan B. Anthony Pro-Life America’s state policy director, said the group is “very encouraged by this landmark win for women and girls.”

“The Court recognized that the abortion pill is dangerous and rolled back Biden’s reckless mail-order abortion scheme,” Daniel said in a statement. “We still believe it never should have been approved in the first place and we look forward to the Supreme Court hearing this case.”

Daniel argued the FDA “has one job: safeguarding the lives and health of Americans.”

“The evidence clearly shows their failure when it comes to the abortion pill,” she said. “First, the FDA inappropriately fast-tracked this dangerous drug for approval without studying its effects in teenage girls. Then under the Obama and Biden administrations, they loosened one safety standard after another — finally approving mail-order abortion drugs and ignoring the critical importance of in-person doctor supervision — and stonewalled those who sought accountability. The rate of abortion pill-related emergency room visits has skyrocketed over 500 percent since it was approved, while the drug manufacturers have made a handsome profit — with investors reaping a 452 percent return on average.”

“The FDA ignored science and placed politics over the safety of women and girls, as well as the lives of countless unborn children,” Daniel argued. “Finally they are beginning to be held accountable.”

Read More Respect Life

Ireland’s abortion rates rise 62 percent over 5 years; Catholic advocates call it ‘a tragedy’

Judge blocks defunding of some, but not all, Planned Parenthood groups

Is NFP finally breaking into medical schools?

Nearly one in three conceptions in England and Wales end in abortion, government figures reveal

Planned Parenthood

Judge blocks, for now, Planned Parenthood defunding provision backed by bishops

Report: US abortions continue post-Dobbs rise in part due to telehealth

Copyright © 2023 OSV News

Print Print

Share
Share on Facebook
Share
Share this
Pin
Pin this
Share
Share on LinkedIn

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • Prince of Peace merges with St. Francis de Sales in Harford County

  • Detroit archbishop fires theologians Ralph Martin, Eduardo Echeverría from seminary

  • Construction underway on new north addition to St. Joseph’s Nursing Home 

  • Archdiocese of Baltimore offers resources for parishes to assist migrants

  • Archbishop Wenski leads Knights on Bikes to pray rosary at Alligator Alcatraz

| Latest Local News |

Archdiocese of Baltimore offers resources for parishes to assist migrants

Third annual gun buyback scheduled for Aug. 9

Driver arrested after crashing into entrance of Esperanza Center

Construction underway on new north addition to St. Joseph’s Nursing Home 

Prince of Peace merges with St. Francis de Sales in Harford County

| Latest World News |

Jubilee of Youth chance to celebrate hope, fraternity in world at war, panel says

New York archdiocese sees hundreds of responses to ‘Called By Name’ program

Can’t afford a Catholic college? Think again. Many offer full tuition options

Detroit archbishop fires theologians Ralph Martin, Eduardo Echeverría from seminary

LA archbishop, joined by business leaders, starts fund to help families affected by ICE raids

| Catholic Review Radio |

CatholicReview · Catholic Review Radio

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • Jubilee of Youth chance to celebrate hope, fraternity in world at war, panel says
  • New York archdiocese sees hundreds of responses to ‘Called By Name’ program
  • Can’t afford a Catholic college? Think again. Many offer full tuition options
  • Detroit archbishop fires theologians Ralph Martin, Eduardo Echeverría from seminary
  • LA archbishop, joined by business leaders, starts fund to help families affected by ICE raids
  • FBI surveilled SSPX priest amid probe of suspected neo-Nazi’s plans for violence
  • Poland’s ‘living memorial’ to St. John Paul II marks 25 years of transforming lives
  • Our faith is not afraid of questions
  • Catholic ‘American Ninja Warrior’ fights world hunger, one obstacle at a time

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2025 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED

en Englishes Spanish
en en